Business
Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference
CHICAGO--(BUSINESS WIRE)-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"text","content":" CHICAGO--(BUSINESS WIRE)--\nXeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will participate in a fireside chat at the 9th Annual SVB Leerink Global Healthcare Conference.\n\n\nDate: Tuesday, February 25, 2020\nTime: 9:00 a.m. ET\nPlace: Lotte New York Palace, New York City\n\n\nA live webcast of the fireside chat can be accessed by visiting ‘Upcoming Events’ in the Investors section on the Company's website at www.xerispharma.com. An archived replay of the webcast will be available for 30 days on the Company's website after the conference.\n\n\nAbout Xeris Pharmaceuticals, Inc.\n\n\nXeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.\n\n\nWith a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial product, Gvoke™. Its proprietary XeriSol™ and XeriJect™ formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. With Xeris’ technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system.\n\n\nXeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on Twitter, LinkedIn or Instagram.\n\n\nForward-Looking Statements \n\n\nAny statements in this press release about future expectations, plans and prospects for Xeris Pharmaceuticals, Inc., including statements regarding the acceptance of Gvoke™ in the marketplace, the market and therapeutic potential of its product candidates, expectations regarding clinical data, the timing or likeliho...